Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Erasca announced financial results for the three months ended June 30, 2026.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Erasca announced financial results for the three months ended June 30, 2026
- Full results and management commentary are provided in Exhibit 99.1
- Disclosure furnished under Regulation FD and generally excluded from Section 18 filing liability
Item EX-99.1 · Exhibit EX-99.1
- ERAS-0015 showed 57% 8-week uORR in 2L+ KRAS G12X PDAC at 32 mg QD, supporting accelerated pancreatic-cancer development
- Favorable safety profile: no DLTs or treatment-related discontinuations, with 100% median relative dose intensity
- July offering raised $632.5M gross proceeds, materially expanding funding for three potentially registration-enabling ERAS-0015 trials
- Q2 R&D expense rose to $35.9M from $21.2M, reflecting intensified clinical and preclinical investment
- Net loss widened to $44.1M, or $0.14 per share, from $33.9M, or $0.12 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.